Abstract: Background: There is a complex relationship between body weight and survival in prostate cancer. While increased BMI is associated with increased prostate cancer …
Abstract: BACKGROUND: Abiraterone and enzalutamide are second generation androgen receptor pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without …
Abstract: BACKGROUND: Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate …